Contract flags
Contract traps share a signature: they cost nothing on signing day and everything on the day you want options. Read the agreement for the leaving terms first, because the exit paragraph is where a vendor's real model of the relationship lives.
- 1. Exclusivity plus non-compete plus long auto-renew, stacked: any one may be negotiable; together they are a cage. Ask: 'Which of these three would you strike?'
- 2. Pricing 'reviewed periodically' or set by a schedule the vendor can amend: your economics are a variable they control. Ask: 'Which numbers are fixed for the term, in the agreement itself?'
- 3. Termination that requires long notice while your data waits until final settlement: leverage disguised as process. Ask: 'What do we receive within 30 days of notice, unconditionally?'
- 4. Verbal promises absent from the document: the demo said white-glove, the agreement says best-efforts. Ask for every load-bearing promise as an addendum, and watch what happens.
Data and ownership flags
In recurring-care businesses the patient relationship is the asset, so ambiguity about who owns it is never accidental. The test is always the same: the agreement's words, not the pitch's.
- 5. 'You own your brand and customers' in marketing, with no matching clause in the agreement: the gap is the answer. Ask: 'Show me the sentence.'
- 6. No export commitment (format, scope, timeline, cost) for your patient list and program data: ownership without portability is a slogan. Ask: 'What file do we get, when, for how much?'
- 7. Records custody nobody can explain: which clinical entity holds charts, and what happens to them on exit, should take a vendor one minute to answer. A muddled answer here predicts muddled compliance everywhere.
Margin traps
Margin mechanics are rarely hidden; they are unitemized. Each of these four is legitimate when disclosed and quantified, and a trap when discovered at scale.
- 8. Medication markup inside a bundled fill price: in recurring-Rx categories the spread on the fill can outweigh every visible fee. Ask: 'Itemize what I pay per fill, per product, and how it moves with your supply cost.'
- 9. Revenue share on top of fees: a percentage of gross plus platform charges taxes your growth twice. Ask for the same relationship priced flat at your 24-month volume and compare.
- 10. Pass-through meters behind a low headline fee (per-visit, per-message, per-integration, per-support-ticket): the price is the sum, not the headline. Ask: 'What does one active patient cost me per month, all meters included, at my volume?'
- 11. Launch pricing with unspecified 'scale pricing' later: if the number at 2,000 patients is real, it can be in writing today. Ask for the volume schedule in the agreement.
The universal margin question, worth asking every vendor identically: 'Walk me through everyone who touches a dollar between the patient's card and my payout.' Precision here predicts the whole relationship; hesitation here is the finding.
Clinical and compliance flags
The first two categories cost you money; this one costs you the company. Every legitimate telehealth program runs on the same triangle (licensed clinicians deciding independently, licensed pharmacies dispensing, your brand owning the program around them), and each flag below is a corner being quietly collapsed.
- 12. Approval-rate talk: any vendor language implying prescriptions are guaranteed, quota-driven, or optimizable ('our conversion from intake to script is X%') treats clinical judgment as a funnel stage. Walk away; regulators read those decks too.
- 13. No state gating in the product: if the demo checkout will sell to any address while clinician licensure covers some states, compliance is a landing-page claim. Ask to place a test order from a state they don't cover, and watch what the product does.
- 14. Certification and claims left as 'your side': a platform whose storefronts routinely fail LegitScript review, or whose templates ship outcome promises and equivalence claims, is exporting its compliance debt to your brand. Ask which certification standards the storefront is built to, and who fixes it when a reviewer objects.
Using this list without becoming paranoid
One flag is a negotiation item; three is a pattern; any clinical flag is a different category (the walking-away kind). The point of the list is not that platforms are adversaries: it is that the good ones answer these fourteen questions quickly, in writing, without flinching, and the difference between vendors is rarely visible anywhere else this early. Pair it with the 25-question diligence checklist for full coverage, the pricing-models guide for the arithmetic, and reference calls to hear how the answers held up a year in.
And yes, run all fourteen on EmbedCare: flat product rates fixed in the agreement, itemized medication economics (included on GLP-1 programs), your brand and data yours in writing, state gating in the product, and storefronts built to certification standards. A vendor that publishes a red-flag list should expect to be graded on it; that is the design.
Frequently asked
- What are the biggest red flags in a telehealth platform contract?
- Four contract patterns: stacked exclusivity plus non-compete plus long auto-renew; pricing the vendor can revise ('reviewed periodically'); exit terms that hold your data until final settlement; and load-bearing promises that exist in the demo but not the document. Each has a one-question test, and the answers belong in the agreement, not the email thread.
- How do telehealth platforms hide their margin?
- Four legitimate-until-unitemized mechanics: medication markup inside bundled fill prices (the big one in recurring-Rx programs), revenue share stacked on top of fees, pass-through meters behind a low headline price, and launch pricing with vague scale pricing later. The exposure question is the same for all four: the all-in cost of one active patient per month at your volume, itemized, in writing.
- What clinical red flags should make me walk away from a telehealth vendor?
- Three, and they are not negotiation items: language implying guaranteed or optimizable prescription approval rates (clinical judgment is not a funnel stage), no state gating in the actual product (checkout selling where licensure doesn't reach), and compliance exported to you (storefront templates carrying outcome or equivalence claims, certification treated as your problem). These are the patterns behind enforcement stories.
- How do I check who owns my patient data on a telehealth platform?
- Read the agreement for three specifics: an ownership clause that matches the marketing claim, an export commitment (format, scope, timeline, cost), and a clear answer on clinical-records custody (which entity holds charts and what happens on exit). 'You own everything' in the pitch with silence in the document is itself the answer.
Want pricing for your program, and the Rx menu that goes with this?
The partner overview in one email; a human follows up with pricing scoped to your program.